Skip to main
  1. Stocks
  2. Pulse Biosciences
  3. Forecast
PLSE

Pulse Biosciences (PLSE) Stock Forecast & Price Target

Pulse Biosciences (PLSE) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pulse Biosciences is attractive fundamentally because its patented nsPFA platform is differentiated, non-thermal, and supported by over 250 issued patents, with early European feasibility data showing 100% procedural success at six months, 96.2% at 12 months, and about 90% freedom from AF/AFL/AT at one year. The company is also converting that clinical promise into visible catalysts, with NANOPULSE-AF enrollment completed in October, NANOCLAMP-AF expected to finish in mid-2027, and CE mark approvals targeted for 4Q27 while a next-generation catheter trial is planned for 2027. Financially, it ended 3Q26 with roughly $189M of cash after using $15.3M in the quarter, and its expanding pipeline in EP, surgical ablation, and thyroid use cases creates multiple shots on goal with potential for capital-efficient partnerships.

Bears say

Pulse Biosciences is viewed negatively because its core commercial traction remains minimal, with 3Q26 Soft Tissue Ablation revenue of $0.4M missing consensus and the company still forecast to generate only $1.8M of revenue in 2026 alongside a loss of ($1.34) per share. Its value proposition is also highly dependent on unproven clinical and regulatory execution, as pivotal trial delays, disappointing outcomes, or FDA submission setbacks could undermine adoption, while the lack of a secured strategic partnership leaves commercialization vulnerable to larger incumbents with far greater resources. Financially, cash was $101.6M at the end of the second quarter of 2026, but rising burn toward $77M in 2026 and continued reliance on equity issuance create meaningful dilution risk.

Pulse Biosciences (PLSE) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulse Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Pulse Biosciences (PLSE) Analyst Forecast & Price Prediction

Get the latest Pulse Biosciences (PLSE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Pulse Biosciences (PLSE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulse Biosciences (PLSE) Forecast

Analysts have given Pulse Biosciences (PLSE) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Pulse Biosciences (PLSE) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulse Biosciences (PLSE)


Pulse Biosciences (PLSE) Analyst Forecast & Price Prediction

Get the latest Pulse Biosciences (PLSE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Pulse Biosciences (PLSE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PLSE stock data and trends